Vivo Capital’s Agile Therapeutics AGRX Stock Holding History

Vivo Capital’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-757	Closed	-$2.21M	–	38
2019 Q2	$2.21M	Hold	757	–	–	0.21%	41
2019 Q1	$2.29M	Hold	757	–	–	0.23%	41
2018 Q4	$872K	Hold	757	–	–	0.11%	40
2018 Q3	$555K	Hold	757	–	–	0.06%	41
2018 Q2	$742K	Hold	757	–	–	0.1%	37
2018 Q1	$3.89M	Hold	757	–	–	0.55%	27
2017 Q4	$4.07M	Hold	757	–	–	0.87%	23
2017 Q3	$6.75M	Hold	757	–	–	1.36%	18
2017 Q2	$5.68M	Hold	757	–	–	1.43%	15
2017 Q1	$4.85M	Hold	757	–	–	1.43%	13
2016 Q4	$8.63M	Sell	757 -253	-25%	-$3.55M	2.84%	11
2016 Q3	$14.1M	Hold	1,010	–	–	4.39%	7
2016 Q2	$15.4M	Hold	1,010	–	–	4.2%	7
2016 Q1	$12.5M	Buy	+1,010	New	+$13M	3.15%	10

Other funds holding AGRX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Vivo Capital's AGRX Position: Q3 2019 in Review

Vivo Capital sold out of Agile Therapeutics (AGRX) in Q3 2019, closing a stake of 757 shares — an estimated $2.21M sold.

Vivo Capital first reported a position in AGRX in Q1 2016 and held it in 14 quarters. The position peaked at $15.4M in Q2 2016. 33 funds tracked by Wall St. Rank hold AGRX as of Q3 2019.

Vivo Capital reported no remaining Agile Therapeutics position as of Q3 2019 after selling out during the quarter.
Vivo Capital sold 757 Agile Therapeutics shares in Q3 2019, an estimated $2.21M.
Vivo Capital first reported a position in Agile Therapeutics in Q1 2016 and held it in 14 quarters.
Vivo Capital's Agile Therapeutics position peaked at $15.4M in Q2 2016.
33 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2019.

Based on Vivo Capital's 13F filing for Q3 2019, filed 13 Nov 2019.